Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425899 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07425899 is a Phase 1 study that is actively recruiting participants, run by AbbVie. The registered enrollment target is 32 participants.
The verdict
NCT07425899, a Phase 1 study, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
Interventions
- DRUG Upadacitinib
- DRUG ABBV-722
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07425899
The ClinicalTrials.gov registry entry for NCT07425899 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Upadacitinib is the first listed.
NCT07425899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07425899 about?
NCT07425899 is a clinical study titled "A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants". This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
What is the current status of trial NCT07425899?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-02-26. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07425899?
The interventions under investigation include: Upadacitinib (DRUG), ABBV-722 (DRUG).
Who is sponsoring clinical trial NCT07425899?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.